Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Investing Activities: 2011-2025

Historic Cash from Investing Activities for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $40.3 million.

  • Enanta Pharmaceuticals' Cash from Investing Activities fell 87.96% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.3 million, marking a year-over-year decrease of 30.72%. This contributed to the annual value of $40.3 million for FY2025, which is 30.72% down from last year.
  • According to the latest figures from FY2025, Enanta Pharmaceuticals' Cash from Investing Activities is $40.3 million, which was down 30.72% from $58.2 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Cash from Investing Activities registered a high of $58.2 million during FY2024, and its lowest value of -$53.6 million during FY2023.
  • Its 3-year average for Cash from Investing Activities is $15.0 million, with a median of $40.3 million in 2025.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 197.60% in 2023, then skyrocketed by 208.69% in 2024.
  • Enanta Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $37.0 million in 2021, then surged by 48.41% to $54.9 million in 2022, then tumbled by 197.60% to -$53.6 million in 2023, then soared by 208.69% to $58.2 million in 2024, then tumbled by 30.72% to $40.3 million in 2025.